Company intelligence / Profile preview
Ginkgo Tree Pharmaceutical
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
Overview
Ginkgo Tree Pharmaceutical (Suzhou) Co., Ltd. is a Chinese biotechnology company founded in 2009 and headquartered in the Suzhou Industrial Park. The company specializes in the discovery and development of innovative small molecule drugs for the treatment of viral infections, including Hepatitis B (HBV), Hepatitis C (HCV), and influenza. Its lead products include Coblopasvir, an HCV NS5A inhibitor approved in China, and Suraxavir Marboxil, an influenza endonuclease inhibitor developed in partnership with Jiangxi Qingfeng Pharmaceutical. Ginkgo Tree is supported by prominent venture capital firms such as Lilly Asia Ventures and Pick-up Capital.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ginkgo Tree Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ginkgo Tree Pharmaceutical.